021-51111890
购物车（）
sales@molnova.cn
GLPG2938
CAS No. 2130996-00-6
GLPG2938 ( 1-(2-Ethoxy-6-(trifluoromethyl)pyridin-4-yl)-3-((5-methyl-6-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)pyridazin-3-yl)methyl)urea )
产品货号. M23968 CAS No. 2130996-00-6
GLPG2938 是一种有效的选择性 S1P2 拮抗剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥1311 | 有现货 |
|
| 10MG | ￥2166 | 有现货 |
|
| 25MG | ￥4166 | 有现货 |
|
| 50MG | ￥5850 | 有现货 |
|
| 100MG | ￥7641 | 有现货 |
|
| 200MG | ￥10170 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥1701 | 有现货 |
|
生物学信息
-
产品名称GLPG2938
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述GLPG2938 是一种有效的选择性 S1P2 拮抗剂。
-
产品描述GLPG2938 is a potent and selective antagonist of S1P2.
-
体外实验GLPG2938 (0.5~5 μM; HPF cells) significantly prevents the S1P-mediated contraction at all tested concentrations.
-
体内实验GLPG2938 (1~10 mg/kg; p.o.) displays a marked protective effect at all dosed tested, resulting in statistically significant reduction of the Ashcroft score.GLPG2938 shows good pharmacokinetics, with long half-life, low clearance, and good bioavailability in all species, especially in dogs. Animal Model:Male C57BL/6 mice Dosage:1~10 mg/kg Administration:P.o.Result:Displayed a marked protective effect at all dosed tested, resulting in statistically significant reduction of the Ashcroft score. ?
-
同义词1-(2-Ethoxy-6-(trifluoromethyl)pyridin-4-yl)-3-((5-methyl-6-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)pyridazin-3-yl)methyl)urea
-
通路GPCR/G Protein
-
靶点S1P Receptor
-
受体S1P2
-
研究领域——
-
适应症——
化学信息
-
CAS Number2130996-00-6
-
分子量503.4
-
分子式C20H19F6N7O2
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 100 mg/mL (198.65 mM)
-
SMILESCCOc1cc(NC(NCc2nnc(-c3cn(C)nc3C(F)(F)F)c(C)c2)=O)cc(C(F)(F)F)n1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis[J]. Journal of Medicinal Chemistry, 2021, 64(9):6037-6058.
